It’s the latest development in the battle between the world’s largest and most expensive medical device makers and a rapidly evolving and rapidly growing body of research suggesting they’re a better fit for many of us.
The latest, from a team of researchers at Columbia University in New York, is an implant that monitors the blood flow in the retina.
It’s part of a growing movement to replace the implants worn by millions of Americans with ones that deliver electrical signals to the retina, which then detect and correct damage.
The technology has been around for years, but new research has suggested it could be the future of vision.
But what is progressive retina disease?
The condition is a form of degenerative retinal loss, caused by damage to the cells that make up the retina itself.
“There are many different forms of progressive retinopathy,” said Dr. David Gittings, director of the National Institute of Neurological Disorders and Stroke (NINDS).
“A lot of them go away in the course of a few months.
Some of them can be permanent.”
The latest findings from the NINDS researchers come from a study published this month in the journal Neurology.
Researchers from the University of Washington in Seattle and the National Eye Institute in Bethesda, Maryland, looked at patients with progressive retinas who had been treated with a number of different types of vision-restoring drugs.
“We looked at what was causing these lesions and what we found was that there was a progressive progression of disease that was occurring over a period of months,” said lead researcher Dr. R. Jeffrey Lohman.
The researchers followed the patients for a year, and found that patients with severe progressive retinsopathy had more problems than those with milder disease.
They also noticed that the more serious the progressive retinoscopy, the worse the symptoms of the disease were.
The study also looked at the levels of the drugs the patients took, including the ones that were being used, and how much they were using.
The drugs that were used in the study were all fairly common, including those that were commonly used to treat severe retinitis pigmentosa, a degenerative form of the degenerative disease that affects up to one in every 10,000 people.
They included steroids and anti-inflammatory drugs like ibuprofen, acetaminophen, and naproxen.
The patients were also followed for months afterward to see how the drugs affected their vision.
“What we found is that the drugs did not seem to be having a significant effect on the progression of the condition,” Dr. Lohmann said.
“What we saw was a progression in progressive retinochondrosis, a progressive degenerative eye disease.”
He said it was unclear why some patients might have more problems with progressive retina disease than others.
“I think there’s something going on in that,” he said.
The research is just one of many that show that some of the most common prescription eye medications are causing some of our most severe degenerative diseases.
The NINES researchers also found that the patients were taking anti-depressants and antipsychotics.
They also noticed patients were getting higher levels of an anti-oxidant medication, which has been associated with the development of other degenerative disorders, like Parkinson’s disease and Alzheimer’s disease.
Dr. Gittins said the drug-induced retinochanthal disorder was also a potential issue in the research.
“If we could figure out what the underlying mechanism is, that would be a big deal because it’s the most commonly reported mechanism of the retinochalopathy,” he explained.
He said the drugs also may not be as effective as they might be.
“A lot is being made out of the fact that people who are using these drugs are showing less progression over time,” he added.
But Dr. Gipps said the most important part of the research was the finding that patients who had severe progressive retina problems had a higher rate of death than patients who did not have the disease.
“This finding is not just an academic thing,” he told ABC News.
“It has real implications for the treatment of progressive degeneration.”
Dr. Lofman said it could also mean that patients are getting more treatments, which is bad news for patients who are already struggling to manage their problems.
“When people don’t have enough medications, it’s more likely that they will develop some side effects that lead to complications that can be life-threatening,” he noted.
“If that is the case, you are not going to get the full benefit of a treatment.”
The National Institutes of Health and the NINEVS are working together to develop a drug to treat progressive retines, Dr. H. Paul McQuillan, director for the National Institutes on Aging’s Division of Clinical and Translational Sciences, said in a statement.
He added that it’s important that patients be aware of the drug’s